BioCardia, Inc.
About BioCardia, Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2017
- $479.0K
- Net income
- -$8.2M
- Total assets
- $3.4M
- Market cap
- $11.7M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating income
- -$8.3M
- Income tax
- $0
- Net income
- -$8.2M
- EPS (basic)
- $-1.23
Balance sheet
- Total assets
- $3.4M
- Current assets
- $2.7M
- Total liabilities
- $2.5M
- Current liabilities
- $2.4M
- Shareholders’ equity
- $895.0K
Cash flow
- Operating cash flow
- -$7.4M
- Investing cash flow
- -$7.0K
- Financing cash flow
- $7.6M
- Net cash flow
- $125.0K
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $11.7M
- Shares outstanding
- 14.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 25, 1995
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $8.2M in FY2017.
- Trading 72% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review BioCardia, Inc..
Write a review
News about BioCardia, Inc.
News & sentiment via Polygon.io
